The study by Assunção-Silva demonstrated the use of synthetic Gly-Arg-Gly-Asp-Ser peptide-modified biodegradable gellan gum-based hydrogels enriched with glial derived neurotrophic factor (GDNF)-coated IONPs to treat severe peripheral nerve injury [424]. The gene discussed is GDNF; the disease is peripheral nerve injury.